Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
In Vivo. 2020 Jul-Aug;34(4):1909-1913. doi: 10.21873/invivo.11987.
BACKGROUND/AIM: Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) have gained popularity especially for treating 1-3 cerebral metastases. Elderly patients benefit from treatment personalisation. A specific survival score was created to facilitate this approach.
Ten characteristics were retrospectively analysed for survival in 104 elderly patients with 1-3 cerebral metastases receiving SRS or FSRT alone using a linear accelerator or Cyberknife®.
On multivariate analysis, better survival was significantly associated with KPS of 90-100 (p=0.049), single lesion (p=0.036), maximum cumulative diameter of all lesions <16 mm (p=0.026) and supratentorial involvement only (p=0.047). Three groups were formed with 12-14 points (n=22), 15-16 points (n=33) and 17-19 points (n=49) with 12-month survival rates of 7%, 34% and 58% (p<0.0001), respectively. Positive predictive values for predicting death ≤12 months and survival ≥12 months were 95% and 54%.
The new score showed very high accuracy in predicting death ≤12 months, but not in predicting survival ≥12 months.
背景/目的：立体定向放射外科（SRS）和分次立体定向放射治疗（FSRT）越来越受欢迎，尤其适用于治疗 1-3 个脑转移瘤。老年患者从治疗个体化中受益。创建了一个特定的生存评分来促进这种方法。
对 104 名接受 SRS 或 FSRT 治疗的 1-3 个脑转移瘤的老年患者（单独使用直线加速器或 Cyberknife®）的 10 个特征进行回顾性分析，以评估其生存情况。
多变量分析显示，更好的生存与 KPS 为 90-100（p=0.049）、单发病变（p=0.036）、所有病变的最大累积直径<16mm（p=0.026）和仅幕上受累（p=0.047）显著相关。将患者分为 3 组，每组 12-14 分（n=22）、15-16 分（n=33）和 17-19 分（n=49），12 个月生存率分别为 7%、34%和 58%（p<0.0001）。预测死亡≤12 个月和生存≥12 个月的阳性预测值分别为 95%和 54%。
新评分在预测死亡≤12 个月方面具有很高的准确性，但在预测生存≥12 个月方面准确性较低。
